Blood-Brain Barrier Opening with MRI-guided Focused Ultrasound Elicits Meningeal Venous Permeability in Humans with Early Alzheimer Disease.


Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
03 2021
Historique:
pubmed: 6 1 2021
medline: 12 10 2021
entrez: 5 1 2021
Statut: ppublish

Résumé

Background Opening of the blood-brain barrier (BBB) induced with MRI-guided focused ultrasound has been shown in experimental animal models to reduce amyloid-β plaque burden, improve memory performance, and facilitate delivery of therapeutic agents to the brain. However, physiologic effects of this procedure in humans with Alzheimer disease (AD) require further investigation. Purpose To assess imaging effects of focused ultrasound-induced BBB opening in the hippocampus of human participants with early AD and to evaluate fluid flow patterns after BBB opening by using serial contrast-enhanced MRI. Materials and Methods Study participants with early AD recruited to a Health Insurance Portability and Accountability Act-compliant, prospective, ongoing phase II clinical trial (ClinicalTrials.gov identifier, NCT03671889) underwent three separate focused ultrasound-induced BBB opening procedures that used a 220-kHz transducer with a concomitant intravenous microbubble contrast agent administered at 2-week intervals targeting the hippocampus and entorhinal cortex between October 2018 and May 2019. Posttreatment effects and gadolinium-based contrast agent enhancement patterns were evaluated by using 3.0-T MRI. Results Three women (aged 61, 72, and 73 years) consecutively enrolled in the trial successfully completed repeated focused ultrasound-induced BBB opening of the hippocampus and entorhinal cortex. Postprocedure contrast enhancement was clearly identified within the targeted brain volumes, indicating immediate spatially precise BBB opening. Parenchymal enhancement resolved within 24 hours after all treatments, confirming BBB closure. Transient perivenous enhancement was consistently observed during the acute phase after BBB opening. Notably, contrast enhancement reappeared in the perivenular regions after BBB closure. This imaging marker is consistent with blood-meningeal barrier permeability and persisted for 24-48 hours before spontaneous resolution. No evidence of intracranial hemorrhage or other adverse effect was identified. Conclusion MRI-guided focused ultrasound-induced blood-brain barrier opening was safely performed in the hippocampi of three participants with Alzheimer disease without any adverse effects. Posttreatment MRI reveals a unique spatiotemporal contrast enhancement pattern that suggests a perivenular immunologic healing response downstream from targeted sites. © RSNA, 2021

Identifiants

pubmed: 33399511
doi: 10.1148/radiol.2021200643
pmc: PMC7924515
doi:

Substances chimiques

Contrast Media 0

Banques de données

ClinicalTrials.gov
['NCT03671889']

Types de publication

Clinical Trial, Phase II Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

654-662

Subventions

Organisme : NINDS NIH HHS
ID : K08 NS089830
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121322
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Brain Stimul. 2014 Mar-Apr;7(2):304-7
pubmed: 24629831
Ann Neurol. 2019 Dec;86(6):975-980
pubmed: 31525269
Clin Sci (Lond). 2017 Aug 10;131(17):2257-2274
pubmed: 28798076
Exp Neurol. 2013 Oct;248:16-29
pubmed: 23707300
PLoS One. 2010 May 11;5(5):e10549
pubmed: 20485502
Mt Sinai J Med. 2010 Jan-Feb;77(1):32-42
pubmed: 20101720
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
PLoS One. 2011;6(11):e27877
pubmed: 22114718
Nat Commun. 2018 Jul 25;9(1):2336
pubmed: 30046032
Sci Rep. 2020 Sep 30;10(1):16144
pubmed: 32999351
J Neurol. 1981;226(1):43-52
pubmed: 6181215
Radiology. 2014 Dec;273(3):736-45
pubmed: 25222068
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Cell Rep. 2013 Nov 14;5(3):646-53
pubmed: 24210819
Nat Rev Neurol. 2011 Mar;7(3):137-52
pubmed: 21304480
Biol Psychiatry. 2018 Feb 15;83(4):311-319
pubmed: 28967385
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997300
Cardiovasc Res. 2018 Sep 1;114(11):1462-1473
pubmed: 29726891
Brain. 2017 Oct 1;140(10):2691-2705
pubmed: 28969373
Alzheimers Res Ther. 2019 Aug 31;11(1):76
pubmed: 31470905

Auteurs

Rashi I Mehta (RI)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Jeffrey S Carpenter (JS)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Rupal I Mehta (RI)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Marc W Haut (MW)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Manish Ranjan (M)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Umer Najib (U)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Paul Lockman (P)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Peng Wang (P)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Pierre-François D'haese (PF)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Ali R Rezai (AR)

From the Departments of Neuroradiology (Rashi I. Mehta, J.S.C., P.W., P.F.D.), Radiology (Rashi I. Mehta, J.S.C.), and Neuroscience (Rashi I. Mehta, J.S.C., M.W.H., P.L., A.R.R.); Rockefeller Neuroscience Institute (Rashi I. Mehta, J.S.C., M.W.H., M.R., U.N., P.L., P.W., P.F.D., A.R.R.); and Departments of Behavioral Medicine and Psychiatry (M.W.H.), Neurosurgery (M.W.H., M.R., A.R.R.), Neurology (M.W.H., U.N.), and Pharmaceutical Sciences (P.L.), West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505; Center for Translational Neuromedicine, University of Rochester, Rochester, NY (Rupal I. Mehta); and Alzheimer's Disease Center and Department of Pathology, Rush University Medical Center, Chicago, Ill (Rupal I. Mehta).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH